Mohammad Shadab Siddiqui1, Mark L Van Natta2, Margery A Connelly3, Raj Vuppalanchi4, Brent A Neuschwander-Tetri5, James Tonascia2, Cynthia Guy6, Rohit Loomba7, Srinivasan Dasarathy8, Julia Wattacheril9, Naga Chalasani4, Arun J Sanyal10. 1. Virginia Commonwealth University, Richmond, VA, United States. Electronic address: Mohammad.siddiqui@vcuhealth.org. 2. John Hopkins University, Baltimore, MD, United States. 3. Laboratory Corporation of America Holdings (LabCorp), Inc, Morrisville, NC, United States. 4. Indiana University, Indianapolis, IN, United States. 5. Saint Louis University, St. Louis, MO, United States. 6. Duke University, Durham, NC, United States. 7. University of California at San Diego, San Diego, CA, United States. 8. Cleveland Clinic, Cleveland, OH, United States. 9. Columbia University, New York, NY, United States. 10. Virginia Commonwealth University, Richmond, VA, United States.
Abstract
BACKGROUND & AIMS:Obeticholic acid (OCA), a farnesoid X receptor agonist, increases total and low-density lipoprotein cholesterol (LDL-C) in patients with non-alcoholic steatohepatitis. In the present study, we aimed to evaluate the impact of OCA therapy on lipoprotein sub-particles. METHOD: This study included 196 patients (99 OCA group and 97 placebo group) who were enrolled in the FLINT trial and had samples available for lipid analysis and liver biopsies at enrollment and end-of-treatment (EOT) at 72 weeks. Very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particles were evaluated at baseline, 12 and 72 weeks after randomization, and 24 weeks following EOT. RESULTS:Baseline lipoprotein profiles were similar among OCA and placebo groups. OCA did not affect total VLDL particle concentrations, but OCA vs. placebo treatment was associated with decreased large VLDL particle concentration at 12 weeks (baseline-adjusted mean: 6.8 vs. 8.9 nmol/L; p = 0.002), mirrored by an increase in less atherogenic, small VLDL particle concentration (33.9 vs. 28.0 nmol/L; p = 0.02). After 12 weeks, total LDL particle concentration was higher in the OCA group than the placebo group (1,667 vs. 1,329 nmol/L; p <0.0001), characterized by corresponding increases in both less atherogenic, large-buoyant LDL (475 vs. 308 nmol/L; p ≤0.001) and more atherogenic small-dense LDL particles (1,015 vs. 872 nmol/L; p = 0.002). The changes in LDL particle concentrations were similar between treatment groups (OCA and placebo) 24 weeks following EOT due to improvement in the OCA cohort. Compared to placebo, a reduction in total HDL particle concentration, particularly large and medium HDL particles, was noted in the OCA-treated patients, but this resolved after drug discontinuation. CONCLUSION:OCA therapy is associated with increases in small VLDL particles, large and small LDL particles, and a reduction in HDL particles at 12 weeks. These lipoprotein concentrations reverted to baseline values 24 weeks after drug discontinuation. LAY SUMMARY: Non-alcoholic steatohepatitis is a chronic liver disease that is associated with an increased risk of developing cirrhosis and cardiovascular disease. Recently, obeticholic acid (OCA), a farnesoid X receptor agonist, improved liver disease but led to an increase in cholesterol. However, the impact of OCA on cholesterol is not well understood. In the present study, we show that OCA therapy is associated with a detrimental increase in lipoprotein levels, which improves after drug discontinuation. ClinicalTrials.gov numbers: NCT01265498.
RCT Entities:
BACKGROUND & AIMS:Obeticholic acid (OCA), a farnesoid X receptor agonist, increases total and low-density lipoprotein cholesterol (LDL-C) in patients with non-alcoholic steatohepatitis. In the present study, we aimed to evaluate the impact of OCA therapy on lipoprotein sub-particles. METHOD: This study included 196 patients (99 OCA group and 97 placebo group) who were enrolled in the FLINT trial and had samples available for lipid analysis and liver biopsies at enrollment and end-of-treatment (EOT) at 72 weeks. Very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particles were evaluated at baseline, 12 and 72 weeks after randomization, and 24 weeks following EOT. RESULTS: Baseline lipoprotein profiles were similar among OCA and placebo groups. OCA did not affect total VLDL particle concentrations, but OCA vs. placebo treatment was associated with decreased large VLDL particle concentration at 12 weeks (baseline-adjusted mean: 6.8 vs. 8.9 nmol/L; p = 0.002), mirrored by an increase in less atherogenic, small VLDL particle concentration (33.9 vs. 28.0 nmol/L; p = 0.02). After 12 weeks, total LDL particle concentration was higher in the OCA group than the placebo group (1,667 vs. 1,329 nmol/L; p <0.0001), characterized by corresponding increases in both less atherogenic, large-buoyant LDL (475 vs. 308 nmol/L; p ≤0.001) and more atherogenic small-dense LDL particles (1,015 vs. 872 nmol/L; p = 0.002). The changes in LDL particle concentrations were similar between treatment groups (OCA and placebo) 24 weeks following EOT due to improvement in the OCA cohort. Compared to placebo, a reduction in total HDL particle concentration, particularly large and medium HDL particles, was noted in the OCA-treated patients, but this resolved after drug discontinuation. CONCLUSION:OCA therapy is associated with increases in small VLDL particles, large and small LDL particles, and a reduction in HDL particles at 12 weeks. These lipoprotein concentrations reverted to baseline values 24 weeks after drug discontinuation. LAY SUMMARY: Non-alcoholic steatohepatitis is a chronic liver disease that is associated with an increased risk of developing cirrhosis and cardiovascular disease. Recently, obeticholic acid (OCA), a farnesoid X receptor agonist, improved liver disease but led to an increase in cholesterol. However, the impact of OCA on cholesterol is not well understood. In the present study, we show that OCA therapy is associated with a detrimental increase in lipoprotein levels, which improves after drug discontinuation. ClinicalTrials.gov numbers: NCT01265498.
Authors: Masumi Ai; Seiko Otokozawa; Bela F Asztalos; Yasuki Ito; Katsuyuki Nakajima; Charles C White; L Adrienne Cupples; Peter W Wilson; Ernst J Schaefer Journal: Clin Chem Date: 2010-04-29 Impact factor: 8.327
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Romeo Papazyan; Xueqing Liu; Jingwen Liu; Bin Dong; Emily M Plummer; Ronald D Lewis; Jonathan D Roth; Mark A Young Journal: J Lipid Res Date: 2018-03-20 Impact factor: 5.922
Authors: B Hameed; N A Terrault; R M Gill; R Loomba; N Chalasani; J H Hoofnagle; M L Van Natta Journal: Aliment Pharmacol Ther Date: 2018-01-14 Impact factor: 8.171
Authors: Mohammad Shadab Siddiqui; Stephen A Harrison; Manal F Abdelmalek; Quentin M Anstee; Pierre Bedossa; Laurent Castera; Lara Dimick-Santos; Scott L Friedman; Katherine Greene; David E Kleiner; Sophie Megnien; Brent A Neuschwander-Tetri; Vlad Ratziu; Elmer Schabel; Veronica Miller; Arun J Sanyal Journal: Hepatology Date: 2018-02-22 Impact factor: 17.425
Authors: Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden Journal: Nat Rev Gastroenterol Hepatol Date: 2021-05-10 Impact factor: 46.802
Authors: Rajaa Nahra; Tao Wang; Kishore M Gadde; Jan Oscarsson; Michael Stumvoll; Lutz Jermutus; Boaz Hirshberg; Philip Ambery Journal: Diabetes Care Date: 2021-05-20 Impact factor: 17.152
Authors: Dany Gaillard; David Masson; Erwan Garo; Maamar Souidi; Jean-Paul Pais de Barros; Kristina Schoonjans; Jacques Grober; Philippe Besnard; Charles Thomas Journal: Int J Mol Sci Date: 2021-07-02 Impact factor: 5.923